Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial

Mary R. Rooney; Dan Wang; J. William McEvoy; S.P. Juraschek; J. Chalmers; Mark Woodward; E. Selvin

doi:10.1016/j.diabres.2021.109148

Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial

Mary R. Rooney
, Dan Wang
, J. William McEvoy
, S.P. Juraschek
, J. Chalmers
, Mark Woodward
, E. Selvin

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

We found that 1,5-anhydroglucitol—a marker of glucose excursions—was not independently associated with subclinical cardiac damage, nor with vascular outcomes, in the ADVANCE Trial. High-sensitivity cardiac troponin T and N-terminal pro-b-type natriuretic peptide provided better prognostic information regarding vascular risk in diabetes than 1,5-anhydroglucitol.

Original language	English
Article number	109148
Number of pages	4
Journal	Diabetes Research and Clinical Practice
Volume	182
DOIs	https://doi.org/10.1016/j.diabres.2021.109148
Publication status	Published - Dec 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

1,5-anhydroglucitol
glucose excursions
subclinical cardiac damage
type 2 diabetes
Cardiac troponin
T and N-terminal
pro-b-type
Natriuretic peptides

Access to Document

10.1016/j.diabres.2021.109148Licence: In Copyright

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119961998&doi=10.1016%2fj.diabres.2021.109148&partnerID=40&md5=3b1d4669b9d203a2800ed9a09f67d787

Cite this

@article{fb0d230345bb49da95d4136bb4fc470c,

title = "Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial",

abstract = "We found that 1,5-anhydroglucitol—a marker of glucose excursions—was not independently associated with subclinical cardiac damage, nor with vascular outcomes, in the ADVANCE Trial. High-sensitivity cardiac troponin T and N-terminal pro-b-type natriuretic peptide provided better prognostic information regarding vascular risk in diabetes than 1,5-anhydroglucitol.",

keywords = "1,5-anhydroglucitol, glucose excursions, subclinical cardiac damage, type 2 diabetes, Cardiac troponin, T and N-terminal, pro-b-type, Natriuretic peptides",

author = "Rooney, \{Mary R.\} and Dan Wang and McEvoy, \{J. William\} and S.P. Juraschek and J. Chalmers and Mark Woodward and E. Selvin",

year = "2021",

month = dec,

doi = "10.1016/j.diabres.2021.109148",

language = "English",

volume = "182",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial

AU - Rooney, Mary R.

AU - Wang, Dan

AU - McEvoy, J. William

AU - Juraschek, S.P.

AU - Chalmers, J.

AU - Woodward, Mark

AU - Selvin, E.

PY - 2021/12

Y1 - 2021/12

N2 - We found that 1,5-anhydroglucitol—a marker of glucose excursions—was not independently associated with subclinical cardiac damage, nor with vascular outcomes, in the ADVANCE Trial. High-sensitivity cardiac troponin T and N-terminal pro-b-type natriuretic peptide provided better prognostic information regarding vascular risk in diabetes than 1,5-anhydroglucitol.

AB - We found that 1,5-anhydroglucitol—a marker of glucose excursions—was not independently associated with subclinical cardiac damage, nor with vascular outcomes, in the ADVANCE Trial. High-sensitivity cardiac troponin T and N-terminal pro-b-type natriuretic peptide provided better prognostic information regarding vascular risk in diabetes than 1,5-anhydroglucitol.

KW - 1,5-anhydroglucitol

KW - glucose excursions

KW - subclinical cardiac damage

KW - type 2 diabetes

KW - Cardiac troponin

KW - T and N-terminal

KW - pro-b-type

KW - Natriuretic peptides

UR - https://www.scopus.com/pages/publications/85119961998

U2 - 10.1016/j.diabres.2021.109148

DO - 10.1016/j.diabres.2021.109148

M3 - Article

SN - 0168-8227

VL - 182

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

M1 - 109148

ER -

Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this